Translating Ideas into Drugs
Enabling new biologies
Expanding pipelines
Collapsing timelines
Decreasing costs
Making medicines better, and making better medicines
AbSci’s revolutionary synthetic biology platform technology offers fully-integrated, AI-assisted, de novo drug discovery and cell line development … in weeks
AbSci’s Protein Printing™ Platform Technology
We screen novel drug variants in the desired scaffold format, and in the cell line that will be used for manufacturing. We specialize in making next-generation biologics that have proven difficult to make in other systems.
We make biologics better at every step, from de novo discovery to lead optimization to cell line development. We streamline the drug creation process for our partners, whatever the stage of the therapeutic candidate.
Our fully-integrated and AI-assisted approach takes weeks (not years), whether we start with a lead candidate for which a partner needs a cell line, or a target against which a partner wants an entirely novel drug (& cell line).
Beyond the savings afforded by reduced failure rates and accelerated timelines, AbSci’s SoluPro® E. coli cell lines offer up to 75% reduction in biologic drug product COGS relative to mammalian systems.
INVESTORS
MANAGEMENT TEAM
Sean McClain
Founder, CEO & Director
Greg Schiffman, CPA
CFO
Matthew Weinstock, Ph.D.
CTO
Lare McClure, Ph.D., JD
General Counsel
Andy Pihl
COO & Director
BOARD OF DIRECTORS
Zachariah Jonasson, Ph.D.
Managing Partner PVP
Sean McClain
Founder, CEO, AbSci
Gustavo Mahler, Ph.D.
CEO, AGC Biologics
V. Bryan Lawlis, Ph.D.
Independent Consultant
Ivana Magovcevic-Liebisch, Ph.D
President & CEO, Vigil Neuroscience
Board Chair
Andy Pihl
COO, AbSci
Karen McGinnis, CPA
Chief Accounting Officer, Illumina
Eli Casdin
CIO, Casdin Capital
Amrit Nagpal
Managing Director, Redmile Group
CAREERS
Join the Team | Translate Ideas into Impact
At AbSci we are defying conventions and innovating without boundaries. We are disrupting an industry with bold ideas and passionate pursuit of new possibilities. We are looking for original thinkers, creative scientists, data-devoted gurus … join us in our quest to redefine possible.
